https://www.selleckchem.com/pr....oducts/spautin-1.htm
5% (95% CI 86.8-98.5) and 100% (subgroupA), and 87.8% (95% CI 79.3-93. and 93.0% (95% CI 84.8-96.8)(subgroup , respectively. Bearman stage 2 veno-occlusive disease (VOD) occurred in 4 very young patients. VA treatment for 8 courses was effective and well tolerated by the subgroup of patients with low-risk ERMS (group A). Four courses of IVA and 5 courses of VA instead of 9 courses of IVA also has very good results. Careful monitoring for liver toxicity is important in very young patients. European union drug regulating authorities